Securities code: 688578 Securities abbreviation: Allist Announcement No.: 2025-003

Shanghai Allist Pharmaceutical Technology Co., Ltd

2024 Annual Results Bulletin Announcement

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

The main financial data of 2024 contained in this announcement are preliminary accounting data, which have not been audited by accounting firms, and the specific data are subject to the 2024 annual report of Shanghai Allist Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company"), and investors are reminded to pay attention to investment risks.

1. Main financial data and indicators for 2024

Unit: RMB 10,000 yuan

Item Current reporting period Same period last year Change (%)

Total operating income 355,777.79 201,818.26 76.29

Operating profit 163,326.89 65,766.80 148.34

Total profit 161,703.88 65,622.12 146.42

Net profit attributable to owners of the parent company 142,412.42 64,417.48 121.08

Deductions attributable to owners of the parent company are not 135,151.86 60,618.43 122.96

Net profit from recurring gains or losses

Basic earnings per share (RMB) 3.16 1.43 120.98

The weighted average return on equity was 30.74% and 17.97%, an increase of 12.77 percentage points

End of the reporting period Beginning of the reporting period Change of change (%)

Total assets 591,407.90 437,649.54 35.13

Owners' equity attributable to the parent company 527,713.87 398,227.79 32.52

Capital (Shares) 45,000.00 45,000.00 -

Net per share attributable to owners of the parent company 11.73 8.85 32.54

Assets (RMB)

Note: 1. The beginning of the reporting period is the same as the end of the previous year as disclosed by law.

2. The financial data and indicators of the reporting period (at the end of the year) are filled in with consolidated statement data, but they are unaudited, and the final results are public

The 2024 annual report of the Division shall prevail.

3. If there is a penny difference in the above increase and decrease range data, it is caused by rounding.

2. Explanation of operating performance and financial situation

(1) The operating situation, financial situation and the main factors affecting the operating performance during the reporting period

1. The main operating conditions and financial situation during the reporting period

During the reporting period, the company achieved a total operating income of 3557.7779 million yuan, a year-on-year increase of 76.29%; ascription

the net profit of the owners of the parent company was 1424.1242 million yuan, a year-on-year increase of 121.08%; The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 1351.5186 million yuan, a year-on-year increase of 122.96%. The above are mainly the company's products during the reporting period, fumetinib mesylate tablets (trade name "Efsha?"). The sales revenue was 350,559.86 million yuan.

At the end of the reporting period, the company's total assets were 591,407.90 million yuan, an increase of 35.13% over the beginning of the period; Belongs to the mother-in-law

the owner's equity of the company was 5277.1387 million yuan, an increase of 32.52% over the beginning of the period; Net assets per share attributable to owners of the parent company was 11.73 yuan, an increase of 32.54% from the beginning of the period.

2. The main factors affecting business performance

The company's core product, fumetinib mesylate tablets, was renewed and included in the national medical insurance catalogue during the reporting period, and the product sales continued to grow, while the company effectively adopted a number of measures to reduce costs and increase efficiency, strictly controlled various costs and expenses, and the company's operating income in 2024, net profit attributable to owners of the parent company, and net profit attributable to owners of the parent company after deducting non-recurring gains and losses achieved significant year-on-year growth.

(2) An explanation of the reasons for the increase or decrease of the relevant items to reach more than 30%.

1. During the reporting period, the company's total operating income increased by 76.29% year-on-year. The main reason is that during the reporting period, the company's core product fumetinib mesylate tablets were renewed and included in the national medical insurance catalog, and the sales revenue continued to grow.

2. During the reporting period, operating profit, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, and basic earnings per share increased by 148.34%, 146.42%, 121.08%, 122.96% and 120.98% respectively over the same period last year. The main reason is that after the company's core product fumetinib mesylate tablets were renewed and included in the national medical insurance catalog, the sales revenue continued to grow, and the company effectively adopted a number of measures to reduce costs and increase efficiency, strictly controlled various costs and expenses, and promoted the company's profits to be greatly improved.

3. During the reporting period, total assets, owners' equity attributable to the parent company and net assets per share attributable to the owners of the parent company increased by 35.13%, 32.52% and 32.54% respectively over the same period last year. The main reason is the company

Operating income and profit increased significantly, and undistributed profits and other owners' equity items increased accordingly, driving the rapid growth of total assets and net assets per share attributable to owners of the parent company.

3. Risk Warning

The main financial data of 2024 contained in this announcement are preliminary accounting data, which have not been audited by accounting firms, and the relevant data may be different from the data disclosed in the company's 2024 annual report, and the specific data are subject to the data disclosed in the company's 2024 annual report, and investors are reminded to pay attention to investment risks.

The announcement is hereby made.

Board of Directors of Shanghai Allist Pharmaceutical Technology Co., Ltd

February 26, 2025